BRIV_adv
Annals of Indian Academy of Neurology
  Users Online: 2972 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size
 
VIEWPOINT
Ahead of Print

Epidemic of Mucormycosis in COVID-19 Pandemic: A Position Paper


1 Department of Neurology, Deenanath Mangeshkar Hospital and Research Center, Pune, India
2 Department of Neurosciences, Apollomedics Super Specialty Hospital, Lucknow, India
3 Brain and Mind Institute, Nagpur, India
4 In-charge: Cerebral Malaria Research Centre, Sardar Patel Medical College and Associated Group of Hospitals, Bikaner, India
5 Department of Neurology, PGIMER, Chandigarh, India
6 Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
7 Department of Neurology, King George Medical University, Lucknow, India
8 Chair, Tropical Neurology Subsection, Indian Academy of Neurology, Surya Neuro Centre, Mumbai, Maharashtra, India

Correspondence Address:
Nirmal Surya,
310, Lotus House, 33A, New Marine lines, Mumbai - 400 020, Maharashtra, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aian.AIAN_421_21

During the second wave of COVID-19 pandemic, there is a sudden increase in number of cases mucormycosis infection in India. This communication by the Tropical Neurology subsection expert group of the Indian Academy of Neurology (IAN) describes the clinical and diagnostic features, treatment of the disease and gives recommendations about the ways forward.


Print this article
 [NEXT]
 [PREV]
 Table of Contents

  Search Pubmed for
 
    -  Kulkarni R
    -  Misra UK
    -  Meshram C
    -  Kochar D
    -  Modi M
    -  Vishnu VY
    -  Garg RK
    -  Surya N
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed391    
    PDF Downloaded31    

Recommend this journal